BV BALTIC Study

Dear Doctors,

Therapeutic decisions in the anti-cancer treatment of CTCL patients are extremely complex. Treatment regimens seem to be poorly understood, which is why, due to the diversity of experiences and resulting scientific cognitive value, we would like to invite you to participate in a nationwide drug registry aimed at assessing the efficacy and safety of brentuximab vedotin treatment in Polish CTCL patients undergoing therapy as part of the Drug Program. Additionally, an important value of the study will be to learn about the characteristics of patients treated with brentuximab and to describe therapeutic regimens used in the treatment of CTCL.

To start collecting data in the registry, it is necessary to conclude an online agreement. Therefore, please register and follow the instructions appearing on the computer screen.

After successful registration and electronic signing of the agreement, please log in using the data obtained during the account creation process.